Use of Raltegravir in Pediatric HIV-1 Infection

Marcia L. Buck, Pharm.D., FCCP, FPPAG; Kristi N. Hofer, Pharm.D; Michelle W. McCarthy, Pharm.D.; FASHP Susan B. Cogut, Pharm.D


Pediatr Pharm. 2012;18(1) 

In This Article

Abstract and Introduction


Treatment options for pediatric patients with HIV-1 infection continue to expand. According to the updated Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection published in August 2011, 17 antiretroviral drugs have a pediatric indication from the Food and Drug Administration (FDA).[1] On December 21, 2011, this number grew again as the FDA extended the approval of raltegravir to include children and adolescents from 2 to 18 years of age.[2,3] Raltegravir was originally approved in 2007 for use in combination with other antiretroviral agents in adults with HIV-1 infection. It is currently the only HIV-1 integrase strand transfer inhibitor (INSTI) available in the United States and offers a safe and effective option for initial therapy for HIV-1 infection or treatment of patients with multidrug-resistant viral mutations.[4,5]


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: